Publication:
Evaluation of using empiric glycopeptides in accordance with the idsa guidelines in hematologic malignancy patients with febrile neutropenia

dc.contributor.authorYalçın, Cumali
dc.contributor.authorÖzkalemkaş, Fahir
dc.contributor.authorÖzkocaman, Vildan
dc.contributor.authorErsal, Tuba
dc.contributor.authorPınar, İbrahim Ethem
dc.contributor.authorOrhan, Bedrettin
dc.contributor.authorCandar, Ömer
dc.contributor.authorÇubukcu, Sinem
dc.contributor.authorKoca, Tuba Güllü
dc.contributor.authorAkyol, Merve Nur
dc.contributor.authorAda, Nevriye Gül
dc.contributor.authorÖzakın, Cüneyt
dc.contributor.authorKazak, Esra
dc.contributor.authorAkalın, Halis
dc.contributor.authorAli, Rıdvan
dc.contributor.buuauthorYALÇIN, CUMALİ
dc.contributor.buuauthorÖZKALEMKAŞ, FAHİR
dc.contributor.buuauthorÖZKOCAMAN, VİLDAN
dc.contributor.buuauthorERSAL, TUBA
dc.contributor.buuauthorPINAR, İBRAHİM ETHEM
dc.contributor.buuauthorORHAN, BEDRETTİN
dc.contributor.buuauthorCANDAR, ÖMER
dc.contributor.buuauthorÇUBUKÇU, SİNEM
dc.contributor.buuauthorGÜLLÜ KOCA, TÛBA
dc.contributor.buuauthorAKYOL, MERVE NUR
dc.contributor.buuauthorADA, NEVRİYE GÜL
dc.contributor.buuauthorÖZAKIN, CÜNEYT
dc.contributor.buuauthorKAZAK, ESRA
dc.contributor.buuauthorAKALIN, EMİN HALİS
dc.contributor.buuauthorALİ, RIDVAN
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Bilim Dalı.
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji Anabilim Dalı.
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji ve Enfeksiyon Hastalıkları Anabilim Dalı.
dc.contributor.orcid0000-0001-9907-1498
dc.contributor.orcid0000-0003-4168-2821
dc.contributor.orcid0000-0001-7530-1279
dc.contributor.orcid0000-0003-3970-2344
dc.contributor.orcid0000-0001-5428-3630
dc.contributor.researcheridKIE-5102-2024
dc.contributor.researcheridJIW-1248-2023
dc.contributor.researcheridFQG-8981-2022
dc.contributor.researcheridAAJ-4354-2021
dc.contributor.researcheridJGM-6601-2023
dc.contributor.researcheridACW-2157-2022
dc.contributor.researcheridEOZ-1609-2022
dc.contributor.researcheridJJB-0254-2023
dc.contributor.researcheridGWQ-5007-2022
dc.contributor.researcheridJYC-2094-2024
dc.contributor.researcheridGNJ-2469-2022
dc.contributor.researcheridAAG-8392-2021
dc.contributor.researcheridAAG-8459-2021
dc.contributor.researcheridAAU-8952-2020
dc.contributor.researcheridGXD-8209-2022
dc.date.accessioned2024-09-27T07:17:26Z
dc.date.available2024-09-27T07:17:26Z
dc.date.issued2022-05-01
dc.description.abstractBackground: This study aimed to evaluate the effects of the appropriate use of empiric glycopeptide therapy in hematologic malignancy patients with febrile neutropenia (FN).Materials and Methods: Patients with FN who were hospitalized in our clinic and started empiric glycopeptide therapy were retrospectively analyzed. Empiric glycopeptide treatment initial indications were determined according to 7 specific criteria in the IDSA guidelines. In addition, the duration of glycopeptide use according to initial indications, causative pathogens in culture positivity, frequency of VRE infection, and the mortality rate was identified.Results: 87 patients were included. Of these, 102 episodes of FN were analyzed. Appropriate use of glycopeptides was observed in 98% of patients. The most common initial indication for glycopeptide was skin or soft-tissue infection, with 52% (n = 53). The mean duration of glycopeptide use was 11 (2-22) days. The time of glycopeptide use was longer in patients with catheter-related infections than in those with severe mucositis and hemodynamic instability (p = 0,041/p = 0,016). The duration of glycopeptide use was shorter in patients with consolidation therapy than in those without consolidation therapy. The mortality rate in culture-positive patients was significantly higher than in culture-negative patients (p = 0.041). At 72 h, glycopeptide therapy was discontinued in 8 of 79 FN episodes within culture-negative patients.Conclusion: This study showed that the mortality rate was higher in culture-positive patients. Additionally, glycopeptides should be discontinued early with no evidence of gram-positive infection.
dc.identifier.doi10.4084/MJHID.2022.039
dc.identifier.eissn2035-3006
dc.identifier.urihttps://doi.org/10.4084/MJHID.2022.039
dc.identifier.urihttps://hdl.handle.net/11452/45379
dc.identifier.urihttps://www.mjhid.org/index.php/mjhid/article/view/4942
dc.identifier.volume14
dc.identifier.wos000818865000010
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherMattioli 1885
dc.relation.journalMediterranean Journal of Hematology and Infectious Diseases
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectInfectious-diseases society
dc.subjectBlood-stream infections
dc.subjectAcute myeloid-leukemia
dc.subjectCancer-patients
dc.subjectMortality
dc.subjectVancomycin
dc.subjectChemotherapy
dc.subjectEpidemiology
dc.subjectManagement
dc.subjectFrequency
dc.subjectEmpiric glycopeptide
dc.subjectFebrile neutropenia
dc.subjectHematologic malignancy
dc.subjectHematology
dc.subjectInfectious diseases
dc.titleEvaluation of using empiric glycopeptides in accordance with the idsa guidelines in hematologic malignancy patients with febrile neutropenia
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication92a2c867-d166-4fba-a661-d0e05a3efdb2
relation.isAuthorOfPublication6d4676a2-f825-4560-bfa8-c7eb6daf748d
relation.isAuthorOfPublication516d4442-e436-45a6-87b9-741a9e213d31
relation.isAuthorOfPublication5ffc1973-3410-4bba-98b1-593db4259ac6
relation.isAuthorOfPublication780690ec-9c57-47ed-a462-d5d676cd36e3
relation.isAuthorOfPublication1486898c-30a2-4e6e-ac20-74a7cb948474
relation.isAuthorOfPublicationa1d03f06-c178-4b63-bd52-2f6468a946d0
relation.isAuthorOfPublication375ef438-7ff8-4a42-97a4-74096fac117f
relation.isAuthorOfPublication98db51d7-7e46-4351-a7d1-13801c5531c0
relation.isAuthorOfPublicationafc46a3c-fb4e-4a67-9791-d1350d032366
relation.isAuthorOfPublicationfdab637d-4edd-4ae9-9c3e-1ffb053f0a01
relation.isAuthorOfPublicatione2a163da-0c46-447e-b253-0b58089d73a6
relation.isAuthorOfPublication44aa832e-512b-446e-b095-bd59406744bd
relation.isAuthorOfPublication4fb46529-3295-4383-97b1-7c494ff32c24
relation.isAuthorOfPublication578cac50-ce4d-4818-8e99-2634ef340753
relation.isAuthorOfPublication.latestForDiscovery92a2c867-d166-4fba-a661-d0e05a3efdb2

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Yalcin_vd_2022.pdf
Size:
436.49 KB
Format:
Adobe Portable Document Format

Collections